



www.acclmp.com

Journal of Applied Biochemistry & Laboratory Medicine

Vol 5 Issue 1, Apr 2024

Printed by
Art-O-Print
43B, Rupnarayan Nandan Lane
Bhowanipur, Kolkata - 700 025

JABLM : The official open-access peer reviewed journal of Association of Clinical Chemistry and Lab Medicine Practitioners (ACCLMP).

ISSN: 2583-4142 (Online)

Official Address:
969, Jessore Road
Kolkata - 700 055

Journal Website: www.jablm.acclmp.com

ACCLMP website : www.acclmp.com

Copyright and Licensing information:

Authors retain the copyright of their papers without restrictions. Authors grant the publisher i.e the ACCLMP, the right of first publication and other non-exclusive publishing rights. This journal follows the terms and conditions of CC BY-NC-ND 4.0 from the Creative Commons License.






First Edition: April 2024

Printed at Art-O-Print




CONTENTS

	Page
I. Introduction to Editorial Team	I-II
II. From the Desk of Editor-in-Chief	III-III
III. Letter to Editor	IV-IV
IV. Review Article.....	1-7
Diagnosis of Hyperprolactinemia by Single Serum Prolactin Determination: Challenges and Recommendations Das Madhumita	
V. Original Article	8-14
Cross-Sectional Analysis of The Use of Different Ratios Of Hepatic Enzymes As Potential Markers For Non-Alcoholic Steatotic Hepatitis (NASH) Sen Susruta, Pathak Indrani, Karmakar Minakshi, Bhattacharjee Nivedita, Choudhuri Sharmistha	
VI. Original Article	15-21
Enhanced serum H2S levels associated with TSH level In Hypothyroid Patients Mallik Lakshmisona Auddya, Pal Prasenjit, Saha Pinaki, Sen Santanu, Sahana Pranab Kumar, Biswas Utpal Kumar	
VII. Original Article.....	22-27
Assessment of the Relationship Between Serum LDH And Ca 125 Values in Pre-Eclampsia Patients Sarkar Biswajit, Ghosh Srabani, Pal Mrinal, Chandra Sangita, Bera Keya	
VIII. Original Article.....	28-37
Association of Serum Homocysteine and Magnesium Levels with Risk and Prognosis in Ischemic Cerebrovascular Accidents Roy Santanu, Saha Avijit, Dutta Arup Kumar, Choudhuri Sharmistha	

Editorial Team of JABLM

Sl No.	Name of Editor	Qualifications	Current Affiliation	Official Address	Official Email Id
1.	<p>Prof. Anindya Dasgupta</p> 	<p>MD (Biochemistry)</p>	<p>Chairman, Scientific Committee, ACCLMP West Bengal Chapter</p>	<p>The Association of Clinical Chemistry & Lab Medicine Practitioners (ACCLMP) 969, Jessore Road Kolkata - 700 055 West Bengal, India</p>	<p>editor.jablm@acclmp.com</p>
2.	<p>Dr. Barnali Das</p> 	<p>MD (Biochemistry) , DNB, PGDHHM</p>	<p>Consultant, Laboratory Medicine, Chair, AACC (India Section) Executive Committee member, Scientific Division, IFCC</p>	<p>Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai</p>	<p>Barnali.Das@kokilabenhospitals.com</p>
3.	<p>Dr. Madhumita Das</p> 	<p>MD (Biochemistry) , PhD (IIT-Guwahati), President ACCLMP (Assam Chapter)</p>	<p>Chief Consultant & HOD</p>	<p>GNRC Medical Lab North Guwahati</p>	<p>madhumita.das@gnrchospitals.com</p>
4.	<p>Dr. Partha Chakrabarti</p> 	<p>MD (Biochemistry) , PhD (Cell & Molecular Biology)</p>	<p>Principal Scientist</p>	<p>CSIR-Indian Institute of Chemical Biology 4, Raja SC Mullick Road Kolkata-700032</p>	<p>pchakrabarti@iicb.res.in</p>
5.	<p>Dr. Mrinal Pal</p> 	<p>DMRT, MD (Biochemistry)</p>	<p>Assistant General Secretary, ACCLMP, Central</p>	<p>The Association of Clinical Chemistry & Lab Medicine Practitioners (ACCLMP) 969, Jessore Road Kolkata - 700 055 West Bengal, India</p>	<p>mrinalpal@acclmp.com</p>

Editorial Team of JABLM

Sl No.	Name of Editor	Qualifications	Current Affiliation	Official Address	Official Email Id
6.	<p>Dr. Sharmistha Choudhuri</p> 	<p>MD Biochemistry (AIIMS, New Delhi), PGDIP Hospital Management (National Institute of Health and Family Welfare (NIHFW), New Delhi)</p>	Assistant Professor	<p>Department of Biochemistry, RG Kar Medical College 1 Khudiram Bose Sarani Kolkata -700004</p>	sharmistha_choudhuri@yahoo.in
7.	<p>Dr. Sayantan Dasgupta</p> 	<p>MD (Biochemistry)</p>	Associate Professor	<p>Department of Biochemistry, North Bengal Medical College Sushrutanagar Siliguri-734012</p>	dr.sayantandasgupta@gmail.com
8.	<p>Dr. Susruta Sen</p> 	<p>MD (Biochemistry), DNB, PG Dip Diabetology, PGDHHM (Symbiosis)</p>	<p>Director, Department of Lab Medicine NABL Lead Assessor President, ACCLMP</p>	<p>CK-Birla Hospitals-CMRI (The Calcutta Medical Research Institute) & BM Birla Heart Research Centre, Kolkata</p>	susrutasen@ckbirlahospitals.com

From the desk of Editor-In-Chief

Are we ready for using RNAi in lab medicine: looking into its major challenges

RNAi was first discovered in the *Petunia* plants when Craig Mello and Andrew Fire revealed how the purple colour in the *Petunia* flowers were converted into faded or white coloured flowers instead of darker ones after the RNAs responsible for the purple colours were introduced into their cell nucleus. Discovery and elucidation of this interference mechanism by RNAs inside the cells took a long period of 8 years from 1990 to 1998, and the whole process was identified as a different mechanism from gene silencing and was named as RNA interference or RNAi. The outcomes of the experiments in *Petunia* flowers were re-inforced when further experiments in the *C. elegans* proved that this silencing was mediated by a dsRNA through an evolutionarily preserved natural process that is the hall mark of RNA interference by small RNAs. After discovery, this mechanism has proved its utility through its application in functional genomics, gene target validation methods and a useful tool for gene knockdown model. Gradually, the RNAi replaced the anti-sense gene silencing technology and ribozyme mediated techniques for its more specific and robust methodology and output. Despite this, many issues remain to be solved before this technique can be utilised for consideration as a routine laboratory method for benefit of patients. Firstly, the inconsistent stability and fragile nature of the dsRNA need to be addressed for improving its functional stability and effective silencing effect inside the cell. Accordingly, addressing this issue, several companies have developed modified siRNA molecules by altering some crucial nucleotides that significantly increased the stability of the siRNA molecules from minutes to days.

The second major limitation was related to the successful delivery of the RNAi molecules into their target cell. Till now the entry of siRNAs into their target cells depend mainly on the quantity of the siRNA to be injected. This experimental evidence in animal models are producing a great restraint for their use in human beings as injection of large quantities of any foreign matter is not possible in humans. This problem has been circumvented by incorporation of siRNAs into cationic liposomes composed of polyethylenimine or synthetic cardiolipin analogue that enhance the penetration power of siRNAs into their cognate target cells significantly. The negatively charged siRNAs, when covered by the cationic lipid vesicles can enter their target cells using endocytosis. These cationic molecules containing the specific siRNAs have been already developed by several biotechnological companies and have smoothened the entry of specific siRNAs into their target cells with minimum side effects. Incorporation of the complementary ligand molecules for specific cell receptors and use of viral vectors are making the delivery of siRNAs into their target cells more specific and accurate. Use of viral vectors are novel in this field regarding the fact that they contain siRNA transcribing machinery like RNA polymerase III promoter in their DNA inserts and can enter into the non dividing cells as neurons. Due to this enormous advantage, viral vectors are now being used as therapeutic agents against HIV, hepatitis C virus (HCV) and muscular dystrophy. The third major problem about the effective and beneficial function of siRNAs inserts are their capability to silence non targeted important genes. These limitations are being minimized by using the microarray analysis to ensure the stringency and fidelity of binding of the siRNAs to their target regions only exclusively.

Lastly, the chances of stimulating the innate immune system of the host is another major disadvantage of siRNA techniques which can be minimized by more accurate scanning of the whole siRNA sequence for any possible immunostimulatory sequences and eliminating them during designing the final siRNA segment.

Removing these obstacles can lead to a much smoother pathway for using the siRNA technology to prevent or cure human diseases now and in future with much more effectivity and lesser side effects.

Professor (Dr) Anindya Dasgupta

Editor in Chief,

Journal of Applied Biochemistry and Lab Medicine.